BRPI1010621A2 - derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso - Google Patents

derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso

Info

Publication number
BRPI1010621A2
BRPI1010621A2 BRPI1010621A BRPI1010621A BRPI1010621A2 BR PI1010621 A2 BRPI1010621 A2 BR PI1010621A2 BR PI1010621 A BRPI1010621 A BR PI1010621A BR PI1010621 A BRPI1010621 A BR PI1010621A BR PI1010621 A2 BRPI1010621 A2 BR PI1010621A2
Authority
BR
Brazil
Prior art keywords
imidazoquinolinones
derivative
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BRPI1010621A
Other languages
English (en)
Inventor
Christian Ragot
Frank Stephan Kalthoff
Frederic Stauffer
Pascal Furet
Robert Mah
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1010621(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI1010621A2 publication Critical patent/BRPI1010621A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1010621A 2009-06-04 2010-06-02 derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso BRPI1010621A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18414109P 2009-06-04 2009-06-04
PCT/EP2010/057719 WO2010139731A1 (en) 2009-06-04 2010-06-02 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES

Publications (1)

Publication Number Publication Date
BRPI1010621A2 true BRPI1010621A2 (pt) 2016-06-21

Family

ID=42697442

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010621A BRPI1010621A2 (pt) 2009-06-04 2010-06-02 derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso

Country Status (30)

Country Link
US (2) US8476294B2 (pt)
EP (1) EP2438064A1 (pt)
JP (1) JP5596137B2 (pt)
KR (1) KR101445458B1 (pt)
CN (1) CN102574845B (pt)
AR (1) AR076949A1 (pt)
AU (1) AU2010255727B2 (pt)
BR (1) BRPI1010621A2 (pt)
CA (1) CA2763821A1 (pt)
CL (1) CL2011003052A1 (pt)
CO (1) CO6470887A2 (pt)
CR (1) CR20110608A (pt)
CU (1) CU24064B1 (pt)
DO (1) DOP2011000373A (pt)
EA (1) EA020715B1 (pt)
EC (1) ECSP11011500A (pt)
GE (1) GEP20156267B (pt)
IL (1) IL216452A0 (pt)
MA (1) MA33332B1 (pt)
MX (1) MX2011012943A (pt)
NI (1) NI201100209A (pt)
NZ (1) NZ596487A (pt)
PE (1) PE20120224A1 (pt)
SG (1) SG176572A1 (pt)
TN (1) TN2011000626A1 (pt)
TW (1) TWI464168B (pt)
UA (1) UA106074C2 (pt)
UY (1) UY32682A (pt)
WO (1) WO2010139731A1 (pt)
ZA (1) ZA201108439B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CA2819955A1 (en) * 2010-12-06 2012-06-14 Piramal Enterprises Limited Substituted imidazoquinoline derivatives
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
US9284315B2 (en) 2011-11-17 2016-03-15 Zuanzhu Pharma Co., Ltd. Three-ring PI3K and/or mTOR inhibitor
WO2014141118A1 (en) * 2013-03-14 2014-09-18 Piramal Enterprises Limited Imidazo[4,5-c]quinoline derivatives and uses thereof
KR102227271B1 (ko) 2013-04-15 2021-03-12 에프엠씨 코포레이션 살진균성 아미드
US9893299B2 (en) 2013-09-11 2018-02-13 Merck Patent Gmbh Heterocyclic compounds
WO2015043398A1 (zh) 2013-09-30 2015-04-02 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
WO2015053402A1 (ja) * 2013-10-11 2015-04-16 国立大学法人東京医科歯科大学 脊髄小脳変性症を予防又は治療するための薬剤
AU2014352463B2 (en) * 2013-11-20 2017-05-11 Beijing Forelandpharma Co. Ltd. Ketone derivatives of imidazoles, pharmaceutical combinations and uses thereof
NO2714752T3 (pt) 2014-05-08 2018-04-21
DK3152199T3 (en) 2014-06-03 2018-11-26 Idorsia Pharmaceuticals Ltd PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS
DK3277681T3 (da) 2015-04-02 2019-07-29 Merck Patent Gmbh Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN110023312A (zh) 2016-10-13 2019-07-16 由卫生与公众服务部部长代表的美利坚合众国 阻止疟疾寄生虫传播的化合物和方法
EP3554490B1 (en) 2016-12-16 2022-02-16 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a t-type calcium channel blocker
WO2018141961A1 (en) 2017-02-06 2018-08-09 Idorsia Pharmaceuticals Ltd A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
MX2020006587A (es) 2017-12-22 2020-12-10 Ravenna Pharmaceuticals Inc Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa.
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN116574099A (zh) * 2019-09-23 2023-08-11 南京征祥医药有限公司 磷酸二酯酶抑制剂及用途
JP7669473B2 (ja) * 2020-09-21 2025-04-28 ウェイ ジョン 血液脳関門透過能力を有する置換１－（３，３－ジフルオロピペリジン－４－イル）－イミダゾ［４，５－ｃ］キノリン－２－オン化合物
CN115136336A (zh) * 2021-01-26 2022-09-30 京东方科技集团股份有限公司 量子点发光器件、显示装置和制作方法
CN116768928A (zh) * 2023-06-15 2023-09-19 上海毕臣生化科技有限公司 一种3-叔丁基-5-硼酸酯基吡啶的合成方法
CN117384154A (zh) * 2023-09-04 2024-01-12 广州医科大学 一种吡咯并喹啉酮化合物、合成方法及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
PT1687305E (pt) 2003-11-21 2008-10-17 Novartis Ag Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
EP1797091A2 (en) 2004-09-14 2007-06-20 Novartis Vaccines and Diagnostics, Inc. Imidazoquinoline compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JP5247458B2 (ja) 2005-11-04 2013-07-24 スリーエム・イノベイティブ・プロパティーズ・カンパニー ヒドロキシ及びアルコキシ置換１ｈ−イミダゾキノリン及び方法
CN102336752A (zh) 2006-11-20 2012-02-01 诺瓦提斯公司 2-甲基-2-[4-(3-甲基-2-氧代-8-喹啉-3-基-2,3-二氢-咪唑并[4,5-c]喹啉-1-基)-苯基]-丙腈的盐和晶型
US9370508B2 (en) * 2007-02-20 2016-06-21 Novartis Ag Imidazoquinolines as dual lipid kinase and mTOR inhibitors
PL2182948T3 (pl) * 2007-07-24 2013-07-31 Novartis Ag Zastosowanie imidazochinolin do leczenia chorób EGFR-zależnych albo chorób wykazujących nabytą oporność wobec środków ukierunkowanych na członków rodziny EGFR
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
JP5519627B2 (ja) 2008-03-26 2014-06-11 ノバルティス アーゲー Ｖｅｇｆ促進性血管新生過程の強力なモジュレーターとしての５イミダゾキノリン誘導体およびピリミジン誘導体
WO2009155527A2 (en) 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
JP5591809B2 (ja) * 2008-09-30 2014-09-17 ファイザー・インク イミダゾ［１，５］ナフチリジン化合物、その医薬への使用、および組成物

Also Published As

Publication number Publication date
AR076949A1 (es) 2011-07-20
EA020715B1 (ru) 2015-01-30
NZ596487A (en) 2012-11-30
TWI464168B (zh) 2014-12-11
MX2011012943A (es) 2012-01-27
AU2010255727A1 (en) 2011-12-08
KR20120034710A (ko) 2012-04-12
CO6470887A2 (es) 2012-06-29
CN102574845A (zh) 2012-07-11
CA2763821A1 (en) 2010-12-09
ECSP11011500A (es) 2012-01-31
KR101445458B1 (ko) 2014-10-07
US20100317657A1 (en) 2010-12-16
CU24064B1 (es) 2014-12-26
CN102574845B (zh) 2015-09-02
TN2011000626A1 (en) 2013-05-24
GEP20156267B (en) 2015-04-14
ZA201108439B (en) 2012-08-29
MA33332B1 (fr) 2012-06-01
NI201100209A (es) 2012-02-02
SG176572A1 (en) 2012-01-30
DOP2011000373A (es) 2011-12-31
JP5596137B2 (ja) 2014-09-24
JP2012528828A (ja) 2012-11-15
PE20120224A1 (es) 2012-04-04
TW201102386A (en) 2011-01-16
CR20110608A (es) 2012-01-16
CL2011003052A1 (es) 2012-08-31
EA201101704A1 (ru) 2012-07-30
UY32682A (es) 2011-01-31
UA106074C2 (uk) 2014-07-25
AU2010255727B2 (en) 2013-02-28
CU20110221A7 (es) 2012-03-15
US20140005163A1 (en) 2014-01-02
WO2010139731A1 (en) 2010-12-09
IL216452A0 (en) 2012-01-31
US8476294B2 (en) 2013-07-02
EP2438064A1 (en) 2012-04-11

Similar Documents

Publication Publication Date Title
BRPI1010621A2 (pt) derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
BR112012013148A2 (pt) formulação farmacêutica e uso
BRPI0915552A2 (pt) derivados de ciclosporina, seu uso e sua composição farmacêutica
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI1008045A2 (pt) derivados de aminotetralina, composições farmacêuticas contendo-os, e seu uso em terapia
BR112013016772A2 (pt) composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado
HRP20160579T1 (hr) Spoj indola i njegova farmaceutska upotreba
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BRPI1009372A2 (pt) compostos, composição farmacêutica e respectivos usos
BRPI1016219A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI1013642A2 (pt) derivado de triazina e composição farmacêutica compreendendo o mesmo
BRPI0721651A2 (pt) Composição farmacêutica
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
EP2419097A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2451274A4 (en) Pharmaceutical compositions
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
BRPI1014914A2 (pt) Composição contendo trehalulose, sua preparação e uso
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
BRPI1006953A2 (pt) composição farmacêutica, e, uso de uma composição
BRPI0907228A2 (pt) Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]